FDA approves novel device for treating breathing difficulty from severe emphysema.
The U.S. Food and Drug Administration approved a new device, the Zephyr Endobronchial Valve (Zephyr…
FDA
FDA permits marketing of device to treat diabetic foot ulcers
The U.S. Food and Drug Administration permitted the marketing of the Dermapace System, the first…
SGLT-2 Inhibitors – Mechanism of Action
12 Dec 2017 SGLT-2 inhibitors Inhibit the Na-glucose co-transporter 2 (SGLT-2) in the kidney to…
FDA warns about illegal use of “injectable silicone implants”.
November 14, 2017 The U.S. Food and Drug Administration issued a safety communication to warn…
FDA approves “DIGITAL pill” with sensor that digitally tracks if patients have ingested their medication.
November 13, 2017 The U.S. Food and Drug Administration approved the first drug in…
FDA clears expanded use of cooling cap to reduce hair loss during chemotherapy
The U.S. Food and Drug Administration cleared the expanded use of a cooling cap, DigniCap…
FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease.
June 22, 2017 The U.S. Food and Drug Administration approved Haegarda, the first C1 Esterase…
FDA approves first generic Strattera for the treatment of ADHD
The U.S. Food and Drug Administration approved the first generic versions of Strattera (atomoxetine) to…
FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin.
The U.S. Food and Drug Administration (FDA) is alerting the public about interim safety results…
Cerliponase alfa approved as enzyme replacement therapy for Batten disease.
April 27, 2017 The U.S. Food and Drug Administration approved Brineura (cerliponase alfa) as a…